
Avaxim 0.5ml Vaccine
Salt Composition: Freeze-dried Live Attenuated Hepatitis A Vaccine (80IU)
Expiry Date: 01/2028
Inclusive of all taxes
1 Vial in a Pack

Avaxim 0.5ml Vaccine
1 Vial in a Pack
Freeze-dried Live Attenuated Hepatitis A Vaccine(80IU)
Salt Composition
Freeze-dried Live Attenuated Hepatitis A Vaccine (80IU)
Storage
2–8°C
Expiry Date
01/2028
Marketer
Sanofi India Ltd
Brand
Avaxim
5966.png&w=1920&q=75)
MAGIC DEALS
Enquire
Apply Promo Code
Available CouponsAvaxim 0.5ml Vaccine
Inclusive of all taxes
In Stock
Authorized
Global Reach
Verified Logistics
The price displayed is inclusive of applicable taxes. Any additional fee (such as shipping fee, handling and/or platform fee etc.) will be clearly disclosed before you complete your purchase.
About The Product
Hepatitis A
The Avaxim 0.5 ml vaccine protects the individual from hepatitis A, which is a liver disease caused by the hepatitis A virus (HAV). It is spread by contaminated water or food or close personal contact with the infected person. The vaccine is produced by killing or inactivating the hepatitis A virus. The Avaxim 0.5 ml vaccine is injected intramuscularly, typically into the upper arm muscle (deltoid), which results in the production of antibodies against the virus without causing the disease. This vaccine is not for other liver diseases or hepatitis B, C, or E. It can be used for both adults and children; for children, it contains a lower amount of antigen, i.e., 80 Elisa Units (EU), while there are 160 EU in 0.5 ml of Avaxim for adults.
Avaxim 0.5ml Vaccine Uses and Indications
Prevention of Hepatitis A
Avaxim 0.5ml Vaccine Side Effects
- Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Avaxim 0.5 ml vaccine.
- But they disappear within a few days naturally as the body adjusts to the vaccine, which requires no medical attention.
- In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.
- Some of the common side effects of the Avaxim 0.5 ml vaccine are: Fatigue Headache Irritability Fever loss of appetite Nausea Pain, redness or swelling at vaccine site
Avaxim 0.5ml Vaccine Dosage and How To Take It
- The Avaxim 0.5 ml vaccine contains inactivated hepatitis A virus and is meant for children in the age group 12 months to 15 years.
- The single 0.5 ml dose is given intramuscularly.
- For children above 2 years, the vaccine is administered in the deltoid muscle of the upper arm, while for children under 2 years of age, the vaccine is given in the anterolateral aspect of the thigh.
- A booster dose of 0.5 ml is recommended for long-term protection, which should be given between 6 and 36 months after the initial dose of vaccination.
- These two doses provide long-lasting immunity for at least 20 years.
- The Avaxim 0.5 ml vaccine should not be self-administered; it should not be given intradermally, intravascularly, or subcutaneously by healthcare experts.
- Do not use the same vaccine or syringe for another vaccine, as there are chance of the products interacting.
- Always check the vial of vaccine before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product.
How Avaxim 0.5ml Vaccine Works
The Avaxim 0.5 ml vaccine contains killed or inactivated hepatitis A virus (HAV) that stimulates the immune system to produce antibodies against the virus but doesn’t cause disease. These antibodies and memory cells formed after taking the vaccine identify and counteract the virus and generate memory for the hepatitis virus, and neutralize it with a stronger immune response upon subsequent exposure within a few hours.
This provides immunity within 2 to 4 weeks and for many years after taking a booster dose.
Safety Advice for Avaxim 0.5ml Vaccine
Excessive alcohol consumption can decrease the immunity of the individual and weaken the liver function. However, moderate levels of alcohol do not interfere with the working of the Avaxim 0.5 ml vaccine, as per the research. People with liver disease caused mainly by drinking alcohol are advised to be vaccinated.
The Avaxim 0.5 ml vaccine should be injected after consulting the doctor; during pregnancy, it is not suggested to take it routinely. However, if the risk of hepatitis A is high, then it may be used if needed after taking advice from the medical experts.
The Avaxim 0.5 ml vaccine can be taken while breastfeeding after discussion with your doctor. It is generally considered safe, and there is no clear evidence found in the clinical data to harm the baby.
Driving after taking the Avaxim 0.5 ml vaccine does not affect or interfere with driving ability or disturb while operating machinery. However, if you get a fever or dizziness after the vaccine, avoid driving until you feel better.
The Avaxim 0.5 ml vaccine is considered safe for people with kidney problems, including individuals on dialysis. The Avaxim 0.5 ml vaccine is considered safe for people with kidney problems, including individuals on dialysis. Although the immune response may be reduced in patients having kidney problems but it is generally recommended to take the vaccine after discussing with your doctor or medical experts.
The Avaxim 0.5 ml vaccine is generally considered beneficial and safe for people with chronic liver disease, and vaccination is strongly recommended for people who are at high risk of getting severe hepatitis A infection.
FAQs About Avaxim 0.5ml Vaccine
The Avaxim 0.5 ml vaccine is injected intramuscularly, typically into the upper arm muscle (deltoid).
The Avaxim 0.5 ml vaccine should not be self-administered; it should not be given intradermally, intravascularly, or subcutaneously by healthcare experts.
References
Abarca, K., Ibáñez, I., Perret, C., Vial, P., & Zinsou, J. A.
(2023). Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
International Journal of Infectious Diseases, 12(3), 270-277. Kim, H., Oh, Y., Thollot, Y., & Bravo, C.
(2024). Post-marketing surveillance of hepatitis A virus vaccine (Avaxim® 160U) in South Korea from 2011 to 2015.
Infectious Diseases and Therapy, 8(1), 105-112. Li, R.
C., Li, Y., Yi, N., Huang, L., Wan, Z., Zhang, Y., & Rasuli, A. (2023).
An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children, and adolescents in China. The Pediatric Infectious Disease Journal, 32(2), e77-e81.
Soysal, A., Gokçe, I., Pehlivan, T., & Bakir, M. (2025).
Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. European journal of pediatrics, 166(6), 533-539.
Zuckerman, J. N., Kirkpatrick, C.
T., & Huang, M. (2023).
Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL.
U) against hepatitis A. Journal of Travel Medicine, 5(1), 18-22.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)